Magnus Thorsson is a leading expert on the business of marijuana. He’s also part of a widening movement to portray the drug as a tool for “personal wellness.”
To that end, he has created the “Experience Framework,” a proposed commercial classification system for the drug based on the sensations users want various strains to provide. To quote Thorsson’s description of the system in a recent op-ed for MJBizDaily:
“Products are categorized across three clearly defined THC ranges — Wellness (less than 10%), Lifestyle (10–18%) and Recreational (more than 18%) — and further grouped by intended effects such as calm, focus, uplift or relief.”
Though this framework is presented as a method to promote wellness and safety through behavioral science and transparency, does it mislead and fail to comply with the core requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Fair Packaging and Labeling Act (FPLA) regarding material facts, warnings, and safety?
The framework, as noted, positions marijuana as if it were a “wellness” tool worthy of being integrated into daily life, suggesting intentional and safe use. However, modern high-THC marijuana — the primary product sold in retail — is linked to severe, well-documented public health risks, including cannabis use disorder (CUD, affecting some 30% of daily users), increased psychosis and schizophrenia risk, and cognitive impairment in adolescents, such as IQ decline and memory deficits. Furthermore, there is no conclusive evidence supporting its efficacy for common conditions like PTSD beyond the VA/DOD Clinical Practice Guidelines rejection.
Based on these observations, it raises questions such labeling of marijuana products with terms like “wellness,” “sleep support,” or “social ease” without equally prominent, mandatory warnings about these severe risks. Would this be misleading under the FD&C and the FPLA? Does this create an illusion of safety and therapeutic benefit that directly contradicts scientific evidence? It appears so.
Thorsson’s model emphasizes “microdosing,” effect descriptions, and dosage instructions, but the Schedule I status of marijuana means there is no established “safe use” recognized by the FDA. The pharmacological dangers of modern high-THC marijuana, including psychosis and cognitive decline, cannot be mitigated by consumer behavior alone. The FD&C Act mandates directions for safe use if a product could be unsafe when used incorrectly. Given the severe risks cited — such as psychosis, cognitive decline, and addiction — and the absence of FDA-approved medical use or dosing guidelines for smoked or vaped marijuana, it is impossible to provide adequate directions that ensure safety. Does Thorsson’s proposed approach, which misleadingly implies that safety can be achieved through consumer choice and labeling, downplay the intrinsic hazards of the product itself? If so, is this done unintentionally? In other words, is he aware that he may be misleading people?
Additionally, Thorsson’s model implicitly portrays high-THC marijuana products as having legitimate medical applications by organizing products by effect and training “budtenders” in “compliant consultations.” However, Thorsson fails to publicly acknowledge (if he doesn’t ignore) a National Academy of Sciences report that found substantial evidence only for three specific conditions using specific cannabinoids, while high-THC smoked or vaped marijuana has “no accepted medical use” according to Schedule I criteria. Does presenting these products with medical-style frameworks and effect claims — without FDA approval — constitute a material misrepresentation? Rescheduling to Schedule III, which Thorsson’s normalization efforts inadvertently facilitate, would falsely legitimize these unapproved, high-risk products as if these were “medicine.”
There are compelling scientific and public health justifications for maintaining marijuana’s Schedule I classification, particularly concerning modern high-THC products prevalent in the retail market that Thorsson promotes. The high potential for abuse is evident: The fact that as noted 30% of daily users develop CUD is a clear indicator that marijuana meets the Schedule I criterion of “high potential for abuse.” Moreover, smoked or vaped high-THC marijuana has no accepted medical use, as confirmed by the NAS report. And the dramatic increase in THC potency has created a pharmacologically distinct and more dangerous substance.
Worse, rescheduling to Schedule III would be catastrophic, falsely legitimizing high-THC products as “medicine” without FDA approval, exacerbating public health risks, and providing a massive financial windfall to the industry through 280E tax relief. This would enable aggressive marketing of dangerous products, prioritizing corporate profits over public safety and removing a crucial barrier to the proliferation of high-potency THC.
Is Thorsson’s approach a dangerous misstep? He is applying behavioral science to normalize and increase sales of a Schedule I substance with documented severe risks. The focus on creating a “welcoming, transparent, and trustworthy” retail environment — while expanding to wellness seekers and older adults — actively normalizes marijuana use while systematically downplaying its severe risks. Transparency about THC content is meaningless without equally prominent, mandated warnings about psychosis, addiction, and cognitive harm. Furthermore, framing “budtenders” as “experience guides” conducting “compliant consultations” exploits behavioral principles to build trust, despite the fundamental lack of FDA-approved medical guidance and the inherent dangers of the products. This misuse of trust serves to sell a high-risk substance.
Thorsson’s explicit goal of increasing sales, basket size, and customer retention (termed “real business benefits”) demonstrates an irresponsible application of sophisticated retail techniques to sell more of a product linked to severe public health harms. This approach directly aids an industry poised to profit enormously from rescheduling, at the public’s expense.
What’s the best response?
We all, together, must take action. The public should actively report marijuana retailers using Thorsson’s model or similar frameworks to the FDA, particularly for products marketed with “wellness,” “medical,” or effect-based claims (e.g., “sleep support,” “mental clarity”) without conspicuous, mandatory warnings about the risks of CUD, psychosis, schizophrenia, and cognitive impairment — especially for adolescents and young adults.
The FDA must also scrutinize the “Experience Framework” and its implementation as potentially promoting the sale of unapproved, misbranded, and high-risk drug products through deceptive marketing and labeling practices. Policymakers must reject rescheduling efforts, emphasizing the scientific evidence presented: the unique dangers of high-THC marijuana, the lack of accepted medical use for smoked or vaped forms, the high abuse potential, and the corporate financial incentives driving reform.
Thorsson’s behavioral approach, though framed as progressive and consumer-friendly, is dangerously deceptive. It systematically downplays the severe risks of high-THC marijuana while exploiting behavioral science to normalize and increase sales of a Schedule I substance with documented public health harms. Upholding marijuana’s Schedule I status and enforcing strict FDA oversight are critical to protecting public safety and preventing the unchecked proliferation of these high-risk products.